^
    23h
    Comparison of postprocessing metrics in multimetabolic APT-weighted CEST and 2-deoxy-D-glucose-CEST-MRI for differentiating breast cancer subtypes in a murine model. (PubMed, Eur Radiol Exp)
    Advanced multimetabolic APTw-CEST and 2-deoxy-D-glucose-CEST postprocessing metrics allowed adequate preclinical murine BC subtyping. AREX showed potential for 2-deoxy-D-glucose-CEST in tumor characterization; however, APTw-CEST remains superior. MTRasym failed to distinguish between tumor subtypes in CEST-MRI.
    Clinical • Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Akeega (abiraterone/niraparib)
    5d
    A brain-driven neural circuit contributes to tissue regeneration in joint cartilage. (PubMed, Ann Rheum Dis)
    Our findings unveil a brain-cartilage circuit that regulates cartilage regeneration, providing valuable insights into the inherent limitations of tissue regeneration and suggesting a promising treatment strategy for enhancing cartilage regeneration.
    Journal
    |
    ADRB2 (Adrenoceptor Beta 2) • PRG4 (Proteoglycan 4)
    |
    Akeega (abiraterone/niraparib)
    5d
    A Clinical Study of ZL-85FA Tablets (clinicaltrials.gov)
    P1/2, N=51, Not yet recruiting, Chengdu Zenitar Biomedical Technology Co., Ltd
    New P1/2 trial
    8d
    Characteristics of auditory event-related potential and prediction of IDH1 mutation in patients with insular glioma. (PubMed, Quant Imaging Med Surg)
    The IDH1-wt group showed higher amplitude of MMN evoked by novel stimulus at Fz and Cz and longer latency of the P300 component evoked by a deviant stimulus at Fz. The combination of AERP parameters yielded a more effective means to predict IDH1 mutation status in patients with insular glioma, which may provide guidance for the surgical intervention of this disease.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type
    |
    Akeega (abiraterone/niraparib)
    14d
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=8, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=30 --> 8 | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Mar 2027 --> Mar 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    Akeega (abiraterone/niraparib)
    22d
    Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. (PubMed, Nucleic Acids Res)
    We also identified and characterised a PARP1 mutation resulting in loss of the enzymatic inhibition and trapping activity of the PARP1-selective inhibitor, saruparib. However, the same mutation increased the trapping ability of other PARPi, namely veliparib and olaparib, without enhancing their enzymatic inhibition activity, a change that led to an increase in efficacy in this BRCA1m model. Together, these data suggest that PARP1 trapping, and not only its enzymatic inhibition, is a key driver for PARPi effectiveness in BRCA1m cancer cells.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • veliparib (ABT-888) • saruparib (AZD5305)
    27d
    Effects of different intensities of electroacupuncture and manual acupuncture at "Shangjuxu" (ST37) on acute inflammatory visceral pain and their relationship with α7nAChR/PI3K/AKT signaling pathway (PubMed, Zhen Ci Yan Jiu)
    Both MA and 2 mA EA (not 3, 4, 6 mA EA) stimulation of ST37 have a similar analgesic effect in acute inflammatory visceral pain rats, which may be related to their function in suppressing the activities of α7nAChR/PI3K/AKT signaling pathway.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Akeega (abiraterone/niraparib)
    1m
    M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov)
    P1, N=3, Terminated, EMD Serono Research & Development Institute, Inc. | N=54 --> 3 | Trial completion date: Apr 2026 --> Dec 2025 | Suspended --> Terminated | Trial primary completion date: Apr 2026 --> Dec 2025; Sponsor Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • M9466
    1m
    M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (clinicaltrials.gov)
    P1, N=141, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    abiraterone acetate • prednisone • tuvusertib (M1774) • M9466 • prednisolone
    1m
    ASCERTAIN: A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (clinicaltrials.gov)
    P1, N=120, Recruiting, AstraZeneca | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    Nubeqa (darolutamide) • saruparib (AZD5305)
    1m
    CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Mayo Clinic | Trial completion date: Sep 2025 --> Mar 2027 | Trial primary completion date: Sep 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    SPOP (Speckle Type BTB/POZ Protein)
    |
    Akeega (abiraterone/niraparib)
    1m
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=86, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1 trial